Schizophrenia Research and Care—Advancements and Challenges
The healthcare system’s ability to diagnose and care for people with schizophrenia has improved in recent decades, as effective pharmacological and psychosocial interventions are now available. However, schizophrenia remains a leading cause of disability and premature mortality. The utilization of p...
-д хадгалсан:
| Формат: | Online |
|---|---|
| Хэл сонгох: | англи |
| Хэвлэсэн: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Нөхцлүүд: | |
| Онлайн хандалт: | ONIX_20240108_9783036598161_121 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
| _version_ | 1869530913022410752 |
|---|---|
| collection | Directory of Open Access Books |
| description | The healthcare system’s ability to diagnose and care for people with schizophrenia has improved in recent decades, as effective pharmacological and psychosocial interventions are now available. However, schizophrenia remains a leading cause of disability and premature mortality. The utilization of pharmacological and psychosocial interventions in the healthcare system, which have the potential to significantly improve the quality of life for people with schizophrenia, heavily depends on medical professionals completing accurate and comprehensive assessments of patients’ psychopathologies, cognitive profiles, physical health statuses and any environmental factors that may influence them. This Special Issue reprint on schizophrenia, from the Journal of Clinical Medicine, presents a collection of articles on current approaches to assessment and treatment, as well as new findings and future perspectives of schizophrenia research and care. |
| format | Online |
| id | doab-20.500.12854ir-132462 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1324622024-03-31T13:08:33Z Schizophrenia Research and Care—Advancements and Challenges Mucci, Armida schizophrenia ERP mismatch negativity MMN P3a illness duration real-life functioning motivation circuits negative symptoms RDoC positive valence system salience system deficit syndrome diagnosis cognitive function social skills training physical comorbidities childhood abuse internalized stigma neutrophil-to-lymphocyte ratio antipsychotics hypothyroidism inflammatory markers expressive deficits experiential deficits functioning quality of life first psychotic episode first episode emotional processing social cognition MCCB MSCEIT real-world studies real-world effectiveness tolerability treatment adherence second-generation antipsychotics long-acting injectable antipsychotics delusional disorders psychosis sex women psychopathology construct schizophrenia spectrum renaming rethinking revising effort expenditure recent-onset schizophrenia persistent negative symptoms motivation neuropeptide S cognitive functioning rehabilitation AEP QEEG switch extrapyramidal symptoms treatment cognitive deficits self-evaluation of negative symptoms health-related quality of life thema EDItEUR::M Medicine and Nursing thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences The healthcare system’s ability to diagnose and care for people with schizophrenia has improved in recent decades, as effective pharmacological and psychosocial interventions are now available. However, schizophrenia remains a leading cause of disability and premature mortality. The utilization of pharmacological and psychosocial interventions in the healthcare system, which have the potential to significantly improve the quality of life for people with schizophrenia, heavily depends on medical professionals completing accurate and comprehensive assessments of patients’ psychopathologies, cognitive profiles, physical health statuses and any environmental factors that may influence them. This Special Issue reprint on schizophrenia, from the Journal of Clinical Medicine, presents a collection of articles on current approaches to assessment and treatment, as well as new findings and future perspectives of schizophrenia research and care. 2024-01-08T14:55:41Z 2024-01-08T14:55:41Z 2023 book ONIX_20240108_9783036598161_121 9783036598161 9783036598178 https://directory.doabooks.org/handle/20.500.12854/132462 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/8502 https://mdpi.com/books/pdfview/book/8502 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-9817-8 10.3390/books978-3-0365-9817-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036598161 9783036598178 208 Basel open access |
| spellingShingle | schizophrenia ERP mismatch negativity MMN P3a illness duration real-life functioning motivation circuits negative symptoms RDoC positive valence system salience system deficit syndrome diagnosis cognitive function social skills training physical comorbidities childhood abuse internalized stigma neutrophil-to-lymphocyte ratio antipsychotics hypothyroidism inflammatory markers expressive deficits experiential deficits functioning quality of life first psychotic episode first episode emotional processing social cognition MCCB MSCEIT real-world studies real-world effectiveness tolerability treatment adherence second-generation antipsychotics long-acting injectable antipsychotics delusional disorders psychosis sex women psychopathology construct schizophrenia spectrum renaming rethinking revising effort expenditure recent-onset schizophrenia persistent negative symptoms motivation neuropeptide S cognitive functioning rehabilitation AEP QEEG switch extrapyramidal symptoms treatment cognitive deficits self-evaluation of negative symptoms health-related quality of life thema EDItEUR::M Medicine and Nursing thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences Schizophrenia Research and Care—Advancements and Challenges |
| title | Schizophrenia Research and Care—Advancements and Challenges |
| title_full | Schizophrenia Research and Care—Advancements and Challenges |
| title_fullStr | Schizophrenia Research and Care—Advancements and Challenges |
| title_full_unstemmed | Schizophrenia Research and Care—Advancements and Challenges |
| title_short | Schizophrenia Research and Care—Advancements and Challenges |
| title_sort | schizophrenia research and care advancements and challenges |
| topic | schizophrenia ERP mismatch negativity MMN P3a illness duration real-life functioning motivation circuits negative symptoms RDoC positive valence system salience system deficit syndrome diagnosis cognitive function social skills training physical comorbidities childhood abuse internalized stigma neutrophil-to-lymphocyte ratio antipsychotics hypothyroidism inflammatory markers expressive deficits experiential deficits functioning quality of life first psychotic episode first episode emotional processing social cognition MCCB MSCEIT real-world studies real-world effectiveness tolerability treatment adherence second-generation antipsychotics long-acting injectable antipsychotics delusional disorders psychosis sex women psychopathology construct schizophrenia spectrum renaming rethinking revising effort expenditure recent-onset schizophrenia persistent negative symptoms motivation neuropeptide S cognitive functioning rehabilitation AEP QEEG switch extrapyramidal symptoms treatment cognitive deficits self-evaluation of negative symptoms health-related quality of life thema EDItEUR::M Medicine and Nursing thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| topic_facet | schizophrenia ERP mismatch negativity MMN P3a illness duration real-life functioning motivation circuits negative symptoms RDoC positive valence system salience system deficit syndrome diagnosis cognitive function social skills training physical comorbidities childhood abuse internalized stigma neutrophil-to-lymphocyte ratio antipsychotics hypothyroidism inflammatory markers expressive deficits experiential deficits functioning quality of life first psychotic episode first episode emotional processing social cognition MCCB MSCEIT real-world studies real-world effectiveness tolerability treatment adherence second-generation antipsychotics long-acting injectable antipsychotics delusional disorders psychosis sex women psychopathology construct schizophrenia spectrum renaming rethinking revising effort expenditure recent-onset schizophrenia persistent negative symptoms motivation neuropeptide S cognitive functioning rehabilitation AEP QEEG switch extrapyramidal symptoms treatment cognitive deficits self-evaluation of negative symptoms health-related quality of life thema EDItEUR::M Medicine and Nursing thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| url | ONIX_20240108_9783036598161_121 |